Microcide: Jetzt wieder einsteigen ??? - 500 Beiträge pro Seite

[hawkk]

Hallo zusammen,

lohnt sich jetzt wieder ein Einstieg bei Microcide ? Die haben ja mächtig korrigiert. Und inzwischen dürften wir doch nah an den Tiefstständen dran sein. Hat sich etwas an den fundamentalen Fakten zu Micro geändert ?

Bitte um Eure Meinungen! Auch Infos !

Hawkk

[hawkk]

Ich habe mir gerade mal deren Homepage angesehen. Ist echt ganz gut aufgemacht und man erhält auch ein paar Infos.

www.microcide.com

Schau mal da vorbei.

Hawkk

[GermanGoody]

Schau Dir mal den Chart in einer halblogarithmischen Darstellung an:



Noch Fragen wegen Bodenbildung oder so

Gruss gg

[hawkk]

Na klar sieht der Chart nicht besonders gut aus. Aber immerhin hat der Tiefststand von vor ein paar Wochen gehalten und wurde nicht nach unten durchbrochen. Und bei Biotechs ist die Chartanalyse eh nicht so aussagekräftig.

Und wenn es allgemein wieder aufwärts geht, da sollte doch Microcide mit Richtung Norden gehen. Von ca. 26 Euro runter auf 7 Euro, da dürfte nicht mehr viel Luft nach unten sein.

Also, ich denke, dass man langsam wieder Positionen aufbauen sollte.

MfG Hawkk

[hawkk]

Hat sonst keiner eine Meinung zu Microcide ???

[Skydancer]

Hallo zusammen,

ich bin schon länger in MCDE investiert und leider auch noch im Minus. Doch aufgrund der Entwicklung der letzten Tage (und nicht zuletzt wegen unten aufgeführten Nachrichten) bin ich recht optimistisch..Mein Break-Even ist nicht mehr weit entfernt..da bin ich mal gespannt......

Quelle der Artikel: http://quotes.freerealtime.com/rt/frt/quotes?symbol=MCDE&typ…

So long, Skydancer



Microcide and Coelacanth Sign Agreement for Discovery of Anti-Viral, Anti-Fungal and Anti-Bacterial Drugs

MOUNTAIN VIEW, Calif. and EAST WINDSOR, N.J., Jun 6, 2000 /PRNewswire via COMTEX/ --
-- Microcide Pharmaceuticals, Inc. (Nasdaq: MCDE) and Coelacanth Corporation
today announced that they will collaborate under a joint research agreement in
which Coelacanth will provide novel libraries of compounds for screening in a
broad range of Microcide assays directed at the identification of innovative
anti-viral, anti-fungal and anti-bacterial therapeutic agents.

Microcide will have the worldwide rights to develop compounds that emerge from
the collaboration, while Coelacanth will receive milestone payments during the
drug development and approval process, and royalties on product sales.

Microcide has developed proprietary whole-cell assays to identify new classes of
antimicrobials active against novel bacterial, fungal or viral gene targets,
including bacterial and fungal efflux pumps. Access to Coelacanth`s
combinatorial compounds, in addition to its own libraries of 250,000 synthetic
compounds and natural product extracts, will provide Microcide with greater
structural diversity to apply against these assays, and ensure a broader set of
potential leads for its medicinal chemistry efforts.

Coelacanth utilizes a suite of highly efficient and scaleable chemical
reactions, ClickChem(TM), in conjunction with its proprietary, "drug-like"
starting materials to create novel, medicinally relevant small molecule
libraries by high-throughput parallel synthesis. The compounds in these
libraries cover broad ranges of molecular themes and they are not present in
commercially available compound libraries. Coelacanth`s high-performance
chemistry strategy is designed to allow for faster identification and
optimization of bioactive compounds.

George H. Miller, Ph.D., Senior Vice President of Research and Development of
Microcide stated, "This is a very exciting collaboration in which the research
strengths of Coelacanth`s rational parallel-synthesis approaches to novel
molecular structures fits well with Microcide`s ability to rapidly evaluate them
as inhibitors of a variety of infectious disease targets, and then advance them
into an intensive lead optimization program."

Alan Main, Ph.D., Chief Executive Officer of Coelacanth commented, "We believe
this powerful combination of Coelacanth`s innovative chemistry platform and
Microcide`s antimicrobial drug discovery expertise will significantly enhance
the discovery of new therapeutic agents in this important field."

Microcide is a biopharmaceutical company whose mission is to discover, develop
and commercialize novel antimicrobials for the improved treatment of serious
bacterial, fungal and viral infections. The Company`s discovery and development
programs address the growing problem of bacterial drug resistance and the need
for improved antifungal and antiviral agents through two principle themes: (i)
Targeted Antibiotics, which focuses on developing novel antibiotics and
antibiotic potentiators to directly address existing bacterial and fungal
resistance problems, and (ii) Targeted Genomics, which utilizes bacterial,
fungal and viral genetics to discover new classes of antimicrobials and other
novel treatments for infectious diseases.

Coelacanth Corporation, founded in 1996, is a privately held company that uses
its proprietary technology, ClickChem(TM), to create sets of novel building
blocks which are used for the production of innovative compound sets that
shorten lead discovery and lead optimization time for drug development.
Coelacanth`s novel, sophisticated screening libraries are offered for sale to
pharmaceutical and biotechnology companies to generate a sustainable revenue
stream. To date, fifteen major companies have become Coelacanth customers. In
parallel, Coelacanth uses its proprietary technologies in drug discovery
collaborations to generate a stream of leads and drug development candidates.

The statements in this press release that relate to the outcome of the research
collaboration between Microcide and Coelacanth and the development of potential
products are forward-looking statements which are subject to the Safe Harbor
provisions created by the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties that could cause
actual results to be materially different, either better or worse, from those
discussed. While Microcide and Coelacanth have formally established a research
agreement, there can be no assurance that any potential products will be
discovered during the research period or that, if discovered, Microcide will
elect to proceed with the development of such potential products. There can be
no assurance that any development candidate selected by Microcide will
successfully proceed through preclinical development and clinical trials, obtain
requisite regulatory approvals for marketing, and result in a commercially
useful product.

SOURCE Microcide Pharmaceuticals, Inc.

--------------------------------------------------------------------------------------------------------------------------------------------

Frost & Sullivan Offers Survey of the Future U.S. Antibiotics Markets

SAN JOSE, Calif., Jun 1, 2000 (BUSINESS WIRE) -- In the midst of increasing
human resistance to antibiotic medications, pharmaceutical companies are
striving to capture lucrative rewards by developing a wealth of new therapeutic
products that will combat resistant strains of infectious pathogens. The Center
for Disease Control and Prevention considers antibiotic resistance the most
important public health issue in the United States today, as an increasing
number of therapies have become less effective in treating bacterial infection.

According to new strategic research by Frost & Sullivan ( www.frost.com ), U.S.
Emerging Antibiotics Markets: Issues and Trends, manufacturers hoping to
introduce novel therapeutic compounds will do so in a highly competitive
environment where generic drugs are more widely accepted among doctors and
consumers. Frost & Sullivan estimates 1999 U.S. antibiotic market revenues at
more than $7 billion, while projecting these numbers to grow to more than $8.5
billion by 2006.

At least five major blockbuster antibiotic drugs will lose their patents before
2006, and generic drugs will continue to force prices down. "With so many
popular drugs coming off patent in the next several years, the generic drug
market is expected to experience significant gains in the antibiotics markets,"
says Frost & Sullivan pharmaceutical industry analyst Christine Fernandez.

Pharmaceutical manufacturers will be forced to compete with these generics as
they become more prevalent, and overall prices are expected to decrease.

Genomic companies are working with pharmaceutical firms in the hope of
accelerating drug discoveries and discovery technologies. Specialty
pharmaceutical companies are looking for agents with novel action mechanisms to
which bacteria have not been exposed and, therefore, are not resistant. The goal
is a new class of antibiotics with predictable efficacy. Biotech companies,
meanwhile, are applying their new discovery tools and technology platforms to
the area of infectious disease in order to increase the rate of drug discovery.

Frost & Sullivan presents the 2000 Market Engineering Awards to companies that
have worked hard to make a positive contribution to the antibiotics industry.
The 2000 Market Engineering Product Innovation Award is presented to Pharmacia
and Upjohn. The 2000 Market Engineering Antibacterial Program Award is given to
Microcide Pharmaceuticals. The 2000 Market Engineering Entrepreneurial Company
Award goes to Cubist Pharmaceuticals, while the 2000 Market Engineering Customer
Focus Award is presented to Bristol-Myers Squibb.

Companies that participated within this industry include: Abbott Laboratories;
Affymetrix Inc.; Agennix; Alchemia, an Australia biotechnology; Antex Biologics
(Gaithersburg, MD); Bayer; Binax; BioMerieux; Bristol-Myers Squibb Company;
Cambridge Antibody Technology PLC; Cubist; Demegen; Eli Lilly; Genome
Therapeutics; Glaxo Wellcome; Hoechst Marion Roussel; Human Genome Sciences,
Inc.; Ibis Therapeutics; ID Biomedical Corporation; Incyte Pharmaceuticals,
Inc.; Inhibitex, Inc.; Intrabiotics; Invision International, Inc.; Johnson &
Johnson; Lexicon Genetics, Inc.; Magainin Pharmaceuticals; Medimmune; Merck &
Company, Inc.; Microcide Pharmaceuticals, Inc.; Micrologix Biotech; Millennium
Pharmaceuticals, Inc.; MRL Diagnostics; Nabi; Neutec Pharm; Novalon
Pharmaceutical Corporation; Oligo Therapeutics, Inc.; Packard Instrument
Company; Paratek Pharmaceuticals, Inc.; PathoGenesis Corporation; Phage
Therapeutics; Pharmacia & Upjohn; Pfizer, Inc.; Rhone-Poulenc Rorer Inc.;
Schering-Plough Corporation; Scriptgen Pharmaceuticals; SmithKline Beecham;
Techlab; Versicor; Wyeth-Ayerst Laboratories, Inc. and Wyeth Lederle Vaccines.

Headquartered in the heart of the Silicon Valley, Frost & Sullivan is a global
leader in international market consulting and training. Frost & Sullivan
monitors the pharmaceutical and biotech industries for market trends, market
measurements and strategies. This ongoing research is used to complement the
Frost & Sullivan Online Pharmaceutical Custom Subscription. Free executive
summaries of both reports are available to the press.

Along with publishing in-depth market consulting research, Frost & Sullivan also
provides custom consulting needs to a variety of multinational companies.


U.S. Emerging Antibiotic Markets: Issues and Trends

Report: 7247-52 Date: May 2000 Price: $3,950

CONTACT: Frost & Sullivan
Nick Mariottini, 530/894-2136
Fax: [phone]
[e-mail]
http://www.frost.com

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

[Skydancer]

Hallo,

es könnte sein, dass heute die News kamen, auf die wir gewartet haben......ein Kurssprung nach oben war schon zu verzeichnen......

Schat mal unter http://quotes.freerealtime.com/rt/frt/quotes?symbol=MCDE&typ… nach.......

Skydancer

[Skydancer]

Nochmal Hallo,

hab grad gemerkt, dass der Link nicht funktioniert. Also hier die Artikel, die von oben aufgeführter Quelle stammen:
(Sorry....wieder mal etwas lang)


Microcide Pharmaceuticals Hires Two Key Executives CFO and VP Clinical Research/Medical Affairs

MOUNTAIN VIEW, Calif., Jun 27, 2000 /PRNewswire via COMTEX/ -- Microcide
Pharmaceuticals, Inc. (Nasdaq: MCDE) today announced two key appointments to its
senior management team. Donald D. Huffman has joined the company as vice
president, finance & corporate development and chief financial officer and
Robert B. Kammer, M.D. has been hired as vice president of clinical research and
medical affairs.

Dr. Kammer has been a member of Microcide`s scientific advisory board and an
infectious disease consultant to the company, following a distinguished career
in developing antibiotics and vaccines at Eli Lilly, Schering-Plough and Aquila
Biopharm. At Lilly he had responsibility for the supervision of antibiotic
clinical trials and completion of NDA packages for FDA review. He was closely
involved with the development programs of nine antibiotics and is perhaps best
known for his contributions to the development of the highly successful
cephalosporin antibiotic, cefaclor, which achieved sales exceeding $1 billion.
At Schering-Plough, he initiated and was responsible for Phase II-IV clinical
research of three successful anti-infective products including clinical trials
which led to the approval of interferon alpha-2b for Hepatitis B and C.

Mr. Huffman was most recently vice president, finance & administration and chief
financial officer at Celtrix Pharmaceuticals, Inc. Prior to Celtrix, Mr. Huffman
was vice president and chief financial officer of Endosonics Corporation, and he
previously served in the same capacity at Qualimatrix, Inc. In addition, Mr.
Huffman held senior financial management positions at Furon Company and Alumax
Inc. He received an M.B.A. from State University of New York at Buffalo and a
B.S. from Pennsylvania State University.

"Don Huffman is joining Microcide at a time of substantial progress, and we are
delighted to have him on our senior management team," said James E. Rurka, the
company`s president and chief executive officer. "He has an extensive background
in finance and strategic planning for Fortune 200, mid-sized and emerging growth
companies. Don`s broad expertise will help us accelerate our forward momentum,
by strengthening the company`s financial, investor relations and corporate
development initiatives."

Rurka added, "Bob Kammer brings a wealth of clinical and business experience to
Microcide as we continue to implement our forward integration strategy of
advancing drug candidates from our own discovery programs. Dr. Kammer`s
experience will also be important to us as we identify and attempt to acquire
later stage development candidates in order to mature our product pipeline."

Microcide is a biopharmaceutical company, whose mission is to discover, develop
and commercialize novel antimicrobials for the improved treatment of serious
bacterial, fungal and viral infections. The company`s discovery and development
programs address the growing problem of bacterial drug resistance and the need
for improved antifungal and antiviral agents through two principle themes: (i)
Targeted Antibiotics, which focuses on developing novel antibiotics and
antibiotic potentiators to directly address existing bacterial and fungal
resistance problems, and (ii) Targeted Genomics, which utilizes bacterial,
fungal and viral genetics to discover new classes of antimicrobials and other
novel treatments for infectious diseases.

The statements in this press release that relate to Microcide developing new
antibiotics for human health applications are forward-looking statements. Such
forward-looking statements involve risks and uncertainties including, without
limitation, the following. There is no assurance that any compounds discovered
will successfully proceed through pre-clinical development and clinical trials,
obtain requisite regulatory approvals for marketing or result in a commercially
useful product. For a discussion of other risks and uncertainties affecting
Microcide`s business, see the company`s annual report on Form 10-K for the year
ended December 31, 1999. Actual results and timing of certain events could
differ materially from those indicated in the forward-looking statements as a
result of these or other factors.

CONTACT: James E. Rurka, President and Chief Executive Officer of Microcide
Pharmaceuticals, Inc., 650-428-3525.

SOURCE Microcide Pharmaceuticals, Inc.


CONTACT: James E. Rurka, President and Chief Executive Officer of
Microcide Pharmaceuticals, Inc., 650-428-3525
/Company News On-Call: http://www.prnewswire.com/comp/113880.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/113880.html or fax,
800-758-5804, ext. 113880

URL: http://www.microcide.com
http://www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.


--------------------------------------------------------------------------------------------------------------------------------------------


Microcide names new CFO and vice president

MOUNTAIN VIEW, Calif., June 27 (Reuters) -
Biopharmaceutical company Microcide Pharmaceuticals Inc.
, said on Tuesday it apppointed a Celtrix
Pharmaceuticals Inc. executive as its new chief
financial officer and vice president of finance and corporate
development.
Donald Huffman was CFO and vice president of finance and
administration at Celtrix, which was acquired earlier this
month by another biopharmaceutical company, Insmed
Pharmaceuticals Inc. .
Microcide also named Robert Kammer, an infectious disease
consultant to the company and member of its scientific advisory
board as its vice president of clinical research and medical
affairs.
Kammer had previously worked with pharmaceutical companies
Eli Lilly & Co. , Schering-Plough Corp . and
Aquila Biopharmaceuticals Inc. developing antibiotics
and vaccines.
Company officials were not immediately available to confirm
who Kammer and Huffman are replacing.
((Deepa Babington, New York Newsroom, 212-859-1700))

[hawkk]

Hi zusammen,

der Ausbruch ist geschafft. Gegen die schwache Nasdaq hat Microcide heute um 18 % auf 9,25 Dollar zugelegt und somit endgültig den 100-Tage-Durchschnitt von unten nach oben deutlich durchbrochen.

Jetzt ist der Weg nach oben wieder frei. Durch die gute Nachricht dürfte es nun auch bei Micro wieder aufwärts gehen. Die letzte Aufwärtsbewegung bei den Biotechs wurde von Micro nicht nachvollzogen, diese könnte jetzt nachgeholt werden. Einmalige kaufgelegenheit mit kurzfristigem Kursziel von 13 Euro.

Mfg Hawkk